DK2683242T3 - Effektive mængder (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl-phenylcarbamat og fremgangsmåder deraf - Google Patents
Effektive mængder (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl-phenylcarbamat og fremgangsmåder deraf Download PDFInfo
- Publication number
- DK2683242T3 DK2683242T3 DK12782326.8T DK12782326T DK2683242T3 DK 2683242 T3 DK2683242 T3 DK 2683242T3 DK 12782326 T DK12782326 T DK 12782326T DK 2683242 T3 DK2683242 T3 DK 2683242T3
- Authority
- DK
- Denmark
- Prior art keywords
- hexahydropyrrolo
- indol
- trimethyl
- procedures
- effective amounts
- Prior art date
Links
- PXFJDRAJSXTPGT-ROPPNANJSA-N [2-[(8br)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl]phenyl] carbamate Chemical compound C1([C@](C2=C3)(C)CCN1C)N(C)C2=CC=C3C1=CC=CC=C1OC(N)=O PXFJDRAJSXTPGT-ROPPNANJSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/041,211 US20120225922A1 (en) | 2011-03-04 | 2011-03-04 | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
| PCT/US2012/026984 WO2012154285A1 (en) | 2011-03-04 | 2012-02-28 | Effective amounts of (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2683242T3 true DK2683242T3 (da) | 2020-07-06 |
Family
ID=46753679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12782326.8T DK2683242T3 (da) | 2011-03-04 | 2012-02-28 | Effektive mængder (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl-phenylcarbamat og fremgangsmåder deraf |
Country Status (10)
| Country | Link |
|---|---|
| US (9) | US20120225922A1 (enExample) |
| EP (1) | EP2683242B8 (enExample) |
| JP (2) | JP2014513065A (enExample) |
| KR (1) | KR20140019361A (enExample) |
| CN (1) | CN103582419A (enExample) |
| AU (1) | AU2012254093B2 (enExample) |
| BR (1) | BR112013022673A2 (enExample) |
| CA (1) | CA2829039C (enExample) |
| DK (1) | DK2683242T3 (enExample) |
| WO (1) | WO2012154285A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
| TW201717938A (zh) * | 2015-08-14 | 2017-06-01 | Ｑｒ製藥股份有限公司 | 治療或預防急性腦部或神經損傷的方法 |
| EP3654957A4 (en) | 2017-05-24 | 2021-06-23 | Annovis Bio, Inc. | PREVENTION OR TREATMENT OF DISEASE CONDITIONS DUE TO METAL DIS-HOMEOSTASIS BY ADMINISTERING POSIPHES TO HEALTHY OR SICK PEOPLE |
| WO2020061404A1 (en) * | 2018-09-21 | 2020-03-26 | Aristea Translational Medicine Corporation | Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions |
| US12281305B2 (en) | 2018-11-21 | 2025-04-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing prion expression |
| US20230002459A1 (en) * | 2019-10-02 | 2023-01-05 | Sangamo Therapeutics, Inc. | Zinc Finger Protein Transcription Factors for Treatment of Prion Disease |
| WO2022245843A1 (en) * | 2021-05-18 | 2022-11-24 | Annovis Bio, Inc. | Inhibition of neurological injuries due to infections via administration of butanetap and analogs thereof |
| US20260028623A1 (en) * | 2022-02-28 | 2026-01-29 | Ionis Pharmaceuticals, Inc. | RNAi AGENTS OF PRION EXPRESSION |
| WO2024123663A1 (en) * | 2022-12-06 | 2024-06-13 | Sri International | Antimicrobial compounds |
| JP2026525835A (ja) * | 2023-06-21 | 2026-08-04 | アノヴィス バイオ，インコーポレイテッド | ポシフェンｄ－酒石酸塩の固体形態 |
| WO2025017530A1 (en) | 2023-07-19 | 2025-01-23 | Assia Chemical Industries Ltd. | Solid state forms of buntanetap and process for preparation thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171750A (en) | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
| US5409948A (en) | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| WO1999002154A1 (en) * | 1997-07-09 | 1999-01-21 | Axonyx | Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias |
| DE60124730T2 (de) | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| WO2002048150A2 (en) | 2000-11-02 | 2002-06-20 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof |
| WO2003024450A1 (en) * | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| US6495700B1 (en) | 2002-01-09 | 2002-12-17 | Axonyx, Inc. | Process for producing phenserine and its analog |
| US20040024043A1 (en) * | 2002-03-22 | 2004-02-05 | Nigel Greig | Method for treating cognitive disorders |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| EP1617844A4 (en) | 2003-04-03 | 2009-07-22 | Prana Biotechnology Ltd | TREATMENT OF NEUROLOGICAL DISEASES |
| US20050013869A1 (en) * | 2003-07-18 | 2005-01-20 | Chaw Cheng Shu | Sustained release formulation for carbamates and a method therefor |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| WO2005091987A2 (en) | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Method of treating down syndrome |
| WO2005089746A1 (en) * | 2004-03-19 | 2005-09-29 | Axonyx, Inc. | Dosage titration for treatment of cognitive disorders |
| EP1604686A1 (en) | 2004-06-08 | 2005-12-14 | Axonyx, Inc. | Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression |
| US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| WO2008134618A2 (en) | 2007-04-27 | 2008-11-06 | The General Hospital Corporation | Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders |
| AU2008262438A1 (en) * | 2007-06-07 | 2008-12-18 | Dynogen Pharmaceuticals, Inc. | Compositions useful for treating gastroesophageal reflux disease |
| JP4690362B2 (ja) * | 2007-07-04 | 2011-06-01 | 株式会社リコー | Ｓｉｍｄ型マイクロプロセッサおよびｓｉｍｄ型マイクロプロセッサのデータ転送方法 |
| WO2010117727A2 (en) * | 2009-03-30 | 2010-10-14 | The General Hospital Corporation | Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions |
| US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
-
2011
- 2011-03-04 US US13/041,211 patent/US20120225922A1/en not_active Abandoned
-
2012
- 2012-02-28 WO PCT/US2012/026984 patent/WO2012154285A1/en not_active Ceased
- 2012-02-28 DK DK12782326.8T patent/DK2683242T3/da active
- 2012-02-28 KR KR1020137025992A patent/KR20140019361A/ko not_active Ceased
- 2012-02-28 BR BR112013022673A patent/BR112013022673A2/pt not_active IP Right Cessation
- 2012-02-28 EP EP12782326.8A patent/EP2683242B8/en active Active
- 2012-02-28 CA CA2829039A patent/CA2829039C/en active Active
- 2012-02-28 AU AU2012254093A patent/AU2012254093B2/en active Active
- 2012-02-28 JP JP2013557757A patent/JP2014513065A/ja not_active Withdrawn
- 2012-02-28 CN CN201280021686.1A patent/CN103582419A/zh active Pending
-
2015
- 2015-06-30 US US14/755,322 patent/US20150374664A1/en not_active Abandoned
-
2017
- 2017-03-06 US US15/450,937 patent/US10383851B2/en active Active
- 2017-12-01 JP JP2017231910A patent/JP2018076332A/ja active Pending
-
2019
- 2019-07-08 US US16/504,813 patent/US11096926B2/en active Active
-
2020
- 2020-08-17 US US16/994,924 patent/US11382893B2/en active Active
- 2020-08-17 US US16/994,921 patent/US11376238B2/en active Active
- 2020-08-17 US US16/994,881 patent/US11400075B2/en active Active
-
2022
- 2022-06-07 US US17/834,367 patent/US12144798B2/en active Active
-
2024
- 2024-10-13 US US18/914,189 patent/US20250114330A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2829039C (en) | 2021-09-14 |
| US20220323413A1 (en) | 2022-10-13 |
| KR20140019361A (ko) | 2014-02-14 |
| BR112013022673A2 (pt) | 2017-03-28 |
| US12144798B2 (en) | 2024-11-19 |
| EP2683242A4 (en) | 2014-09-03 |
| JP2014513065A (ja) | 2014-05-29 |
| US11376238B2 (en) | 2022-07-05 |
| EP2683242A1 (en) | 2014-01-15 |
| JP2018076332A (ja) | 2018-05-17 |
| US20150374664A1 (en) | 2015-12-31 |
| US11382893B2 (en) | 2022-07-12 |
| US10383851B2 (en) | 2019-08-20 |
| US11096926B2 (en) | 2021-08-24 |
| AU2012254093B2 (en) | 2015-08-06 |
| US11400075B2 (en) | 2022-08-02 |
| US20190381007A1 (en) | 2019-12-19 |
| US20200375947A1 (en) | 2020-12-03 |
| EP2683242B8 (en) | 2020-06-03 |
| US20210093610A1 (en) | 2021-04-01 |
| US20170304266A1 (en) | 2017-10-26 |
| CA2829039A1 (en) | 2012-11-15 |
| US20200375948A1 (en) | 2020-12-03 |
| AU2012254093A1 (en) | 2013-09-26 |
| US20120225922A1 (en) | 2012-09-06 |
| CN103582419A (zh) | 2014-02-12 |
| US20250114330A1 (en) | 2025-04-10 |
| WO2012154285A1 (en) | 2012-11-15 |
| EP2683242B1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2688642A4 (en) | neurostimulator | |
| SI2793578T1 (sl) | N-arilamidin-substituirani derivati trifluoroetilsulfida kot akaricidi in insekticidi | |
| EP2720749A4 (en) | PERCUTANEOUS TIBIAL VACIMINATOR | |
| DK2707031T3 (da) | Protein-active agent conjugates and method for preparing the same | |
| EP2726687A4 (en) | IMPROVED BASE PLATES | |
| EP2783064A4 (en) | CUTTING ROLL PLACEMENT ON PDC PIECES | |
| BR112013029608A2 (pt) | "base de liquidificador" | |
| EP2672981A4 (en) | MULTIPARTICULAR L-MENTHOL FORMULATION AND CORRESPONDING METHODS | |
| BR112013023056A2 (pt) | derivados de oxaespiro [2,5] octano e análogos | |
| ZA201400901B (en) | Supramolecular capsules | |
| EP2683242A4 (en) | EFFICIENT AMOUNT OF (3AR-) 1,3A, 8-TRIMETHYL-1,2,3,3A, 8,8A-HEXAHYDROPYRROLO- [2,3-B] INDOL-5-YL-PHENYL CARBAMATE AND PROCESS THEREFOR | |
| HUE045612T2 (hu) | Immunszuppresszáns készítmények | |
| EP2742033A4 (en) | FLAVONOID COMPOUNDS AND METHODS OF USE | |
| BR112013017477A2 (pt) | protetor de furo | |
| EP2762010A4 (en) | TASTE-IMPROVED SUBSTANCE | |
| EP2684467A4 (en) | TASTE IMPROVING AGENT | |
| ZA201402453B (en) | Insecticidal 2-methoxybenzamide derivatives | |
| BR112012022411A2 (pt) | articulador | |
| SG10201601853XA (en) | Pericyte progenitors from peripheral blood | |
| ITBO20110590A1 (it) | Procedimento e apparecchiatura per l'estrazione di bava di chiocciola. | |
| BR302012001925S1 (pt) | "configuração aplicada em calota" | |
| EP2684382A4 (en) | EARPHONES | |
| IT1398997B1 (it) | Giostra per l'allenamento di cavalli | |
| BR112013030369A2 (pt) | composições de cb-183,315 e métodos relacionados | |
| EP2760219A4 (en) | Headphone device |